Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 34386 | 10.19 |
09:34 ET | 5896 | 10.24 |
09:36 ET | 9935 | 10.1812 |
09:38 ET | 10547 | 10.26 |
09:39 ET | 138865 | 10.559 |
09:41 ET | 27514 | 10.51 |
09:43 ET | 30802 | 10.27 |
09:45 ET | 11225 | 10.285 |
09:48 ET | 11760 | 10.39 |
09:50 ET | 6965 | 10.4599 |
09:52 ET | 26329 | 10.39 |
09:54 ET | 9687 | 10.36 |
09:56 ET | 6739 | 10.415 |
09:57 ET | 10140 | 10.31 |
09:59 ET | 4593 | 10.27 |
10:01 ET | 11043 | 10.38 |
10:03 ET | 5344 | 10.26 |
10:06 ET | 9242 | 10.24 |
10:08 ET | 5288 | 10.32 |
10:10 ET | 4716 | 10.3288 |
10:12 ET | 4759 | 10.36 |
10:14 ET | 6444 | 10.295 |
10:15 ET | 8885 | 10.31 |
10:17 ET | 13733 | 10.25 |
10:19 ET | 6854 | 10.205 |
10:21 ET | 4118 | 10.14 |
10:24 ET | 6096 | 10.14 |
10:26 ET | 2751 | 10.175 |
10:28 ET | 13261 | 10.21 |
10:30 ET | 7591 | 10.2 |
10:32 ET | 21158 | 10.315 |
10:33 ET | 5415 | 10.29 |
10:35 ET | 3755 | 10.2 |
10:37 ET | 19535 | 10.21 |
10:39 ET | 7290 | 10.17 |
10:42 ET | 1421 | 10.15 |
10:44 ET | 3150 | 10.155 |
10:46 ET | 1200 | 10.21 |
10:48 ET | 1110 | 10.21 |
10:50 ET | 1510 | 10.14 |
10:51 ET | 6920 | 10.13 |
10:53 ET | 2953 | 10.1476 |
10:55 ET | 3485 | 10.28 |
10:57 ET | 7226 | 10.34 |
11:00 ET | 2753 | 10.3278 |
11:02 ET | 6516 | 10.4 |
11:04 ET | 8626 | 10.41 |
11:06 ET | 7372 | 10.47 |
11:08 ET | 1489 | 10.43 |
11:09 ET | 5418 | 10.4 |
11:11 ET | 2204 | 10.41 |
11:13 ET | 15353 | 10.45 |
11:15 ET | 3457 | 10.465 |
11:18 ET | 5315 | 10.4 |
11:20 ET | 3484 | 10.41 |
11:22 ET | 2450 | 10.375 |
11:24 ET | 3556 | 10.355 |
11:26 ET | 2648 | 10.325 |
11:27 ET | 1760 | 10.315 |
11:29 ET | 1160 | 10.32 |
11:31 ET | 1399 | 10.29 |
11:33 ET | 3297 | 10.2612 |
11:36 ET | 3515 | 10.31 |
11:38 ET | 1200 | 10.275 |
11:40 ET | 2004 | 10.29 |
11:42 ET | 2889 | 10.25 |
11:44 ET | 2725 | 10.205 |
11:45 ET | 2100 | 10.185 |
11:47 ET | 4968 | 10.1986 |
11:49 ET | 3900 | 10.19 |
11:51 ET | 900 | 10.195 |
11:54 ET | 2688 | 10.18 |
11:56 ET | 2138 | 10.2 |
11:58 ET | 1438 | 10.2 |
12:00 ET | 2040 | 10.18 |
12:02 ET | 2792 | 10.2 |
12:03 ET | 1554 | 10.18 |
12:05 ET | 1982 | 10.16 |
12:07 ET | 1246 | 10.17 |
12:09 ET | 2769 | 10.175 |
12:12 ET | 913 | 10.17 |
12:14 ET | 4952 | 10.23 |
12:16 ET | 1334 | 10.255 |
12:18 ET | 5616 | 10.24 |
12:20 ET | 3260 | 10.235 |
12:21 ET | 3317 | 10.245 |
12:23 ET | 1941 | 10.2402 |
12:25 ET | 2256 | 10.25 |
12:27 ET | 2100 | 10.235 |
12:30 ET | 1184 | 10.22 |
12:32 ET | 2546 | 10.1812 |
12:34 ET | 4623 | 10.21 |
12:36 ET | 3100 | 10.245 |
12:38 ET | 4634 | 10.24 |
12:39 ET | 2800 | 10.235 |
12:41 ET | 1300 | 10.27 |
12:43 ET | 1837 | 10.275 |
12:45 ET | 734 | 10.265 |
12:48 ET | 3637 | 10.255 |
12:50 ET | 6064 | 10.29 |
12:52 ET | 800 | 10.26 |
12:54 ET | 3737 | 10.26 |
12:56 ET | 1670 | 10.27 |
12:57 ET | 1522 | 10.255 |
12:59 ET | 3641 | 10.27 |
01:01 ET | 1931 | 10.25 |
01:03 ET | 7834 | 10.235 |
01:06 ET | 2751 | 10.28 |
01:08 ET | 3273 | 10.28 |
01:10 ET | 4149 | 10.33 |
01:12 ET | 2756 | 10.35 |
01:14 ET | 875 | 10.36 |
01:15 ET | 5546 | 10.355 |
01:17 ET | 1617 | 10.37 |
01:19 ET | 1325 | 10.3512 |
01:21 ET | 1742 | 10.37 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.2B | -2.3x | --- |
Prothena Corporation PLC | 1.2B | -8.3x | --- |
Immatics NV | 1.1B | -8.4x | --- |
Arcus Biosciences Inc | 1.4B | -3.8x | --- |
Silence Therapeutics PLC | 990.5M | -16.3x | --- |
Protagonist Therapeutics Inc | 1.5B | -17.7x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
---|---|
Revenue (TTM) | $86.2M |
Shares Outstanding | 135.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-4.59 |
Book Value | $11.80 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 14.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -794.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.